Palvella Therapeutics (NASDAQ:PVLA) Sets New 12-Month High – Should You Buy?

Shares of Palvella Therapeutics, Inc. (NASDAQ:PVLA) hit a new 52-week high during trading on Monday . The company traded as high as $151.36 and last traded at $152.2460, with a volume of 245279 shares trading hands. The stock had previously closed at $148.21.

Analyst Ratings Changes

PVLA has been the subject of a number of research reports. Chardan Capital reaffirmed a “buy” rating and set a $240.00 price target on shares of Palvella Therapeutics in a research report on Thursday, May 21st. HC Wainwright raised their price objective on Palvella Therapeutics from $255.00 to $270.00 and gave the company a “buy” rating in a research report on Tuesday, March 24th. Wall Street Zen lowered Palvella Therapeutics from a “hold” rating to a “sell” rating in a research report on Saturday, April 11th. Finally, Stephens reissued an “overweight” rating and issued a $220.00 price objective on shares of Palvella Therapeutics in a research report on Thursday, May 21st. One analyst has rated the stock with a Strong Buy rating, fourteen have issued a Buy rating and one has assigned a Sell rating to the company. According to MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and an average target price of $199.53.

Palvella Therapeutics Stock Performance

The firm has a market capitalization of $2.22 billion, a P/E ratio of -36.89 and a beta of -0.14. The stock has a fifty day moving average price of $118.78 and a two-hundred day moving average price of $110.27.

Palvella Therapeutics (NASDAQ:PVLA) last announced its quarterly earnings data on Thursday, May 7th. The company reported ($1.20) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.90) by ($0.30). As a group, research analysts anticipate that Palvella Therapeutics, Inc. will post -5.26 earnings per share for the current fiscal year.

Insider Activity

In other news, COO Kathleen Goin sold 4,302 shares of Palvella Therapeutics stock in a transaction dated Wednesday, June 17th. The shares were sold at an average price of $110.73, for a total value of $476,360.46. Following the completion of the transaction, the chief operating officer directly owned 2,154 shares of the company’s stock, valued at approximately $238,512.42. The trade was a 66.64% decrease in their position. The transaction was disclosed in a filing with the SEC, which is accessible through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders own 17.20% of the company’s stock.

Institutional Investors Weigh In On Palvella Therapeutics

Institutional investors and hedge funds have recently bought and sold shares of the business. First Light Asset Management LLC boosted its stake in Palvella Therapeutics by 38.3% in the first quarter. First Light Asset Management LLC now owns 980,758 shares of the company’s stock valued at $122,251,000 after acquiring an additional 271,617 shares during the period. Suvretta Capital Management LLC lifted its holdings in shares of Palvella Therapeutics by 8.5% in the 4th quarter. Suvretta Capital Management LLC now owns 892,400 shares of the company’s stock worth $93,408,000 after purchasing an additional 70,000 shares during the last quarter. Jennison Associates LLC raised its holdings in Palvella Therapeutics by 65.3% during the 1st quarter. Jennison Associates LLC now owns 640,611 shares of the company’s stock worth $79,852,000 after buying an additional 253,128 shares during the period. Vanguard Group Inc. lifted its stake in Palvella Therapeutics by 13.3% during the fourth quarter. Vanguard Group Inc. now owns 560,616 shares of the company’s stock valued at $58,680,000 after buying an additional 65,960 shares in the last quarter. Finally, State Street Corp lifted its stake in Palvella Therapeutics by 206.3% during the fourth quarter. State Street Corp now owns 420,462 shares of the company’s stock valued at $44,010,000 after buying an additional 283,211 shares in the last quarter. Institutional investors and hedge funds own 40.11% of the company’s stock.

Palvella Therapeutics Company Profile

Palvella Therapeutics, Inc (NASDAQ: PVLA) is a clinical‐stage biopharmaceutical company devoted to the discovery and development of innovative therapies for immunological and inflammatory diseases. The company employs a proprietary small‐molecule and biologics platform to identify and modulate key molecular pathways that drive neutrophil‐ and complement‐mediated inflammation, aiming to deliver targeted treatment options for patients with significant unmet medical needs.

Palvella’s pipeline comprises several preclinical assets designed to address both prevalent chronic inflammatory conditions and rare autoinflammatory syndromes.